SLNO

Soleno Therapeutics, Inc. is a biotechnology company in the healthcare sector with 152 employees. The company's market capitalization stands at $2.43 billion. The financials of Soleno Therapeutics indicate significant losses, with a net income of -$78,450,000 and an EBITDA of -$82,259,000 over the trailing twelve months. Despite this, the company has maintained a gross margin of 98.1% and an operating margin of 34.4%. However, its profit margin is -79.5%, indicating substantial losses. The balance sheet shows $498.93 million in cash and $52.66 million in debt, resulting in a debt to equity ratio of 10.64. The valuation metrics are mixed, with a forward P/E of -19.92 and an EV/EBITDA of -25.37. These figures indicate that the company's stock price is significantly lower than its earnings or cash flow. The price to book ratio stands at 4.91, while the price to sales ratio is 24.61.